Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant cadonilimab plus chemotherapy for resectable high-grade salivary gland carcinoma (Phase II)
ChiCTR2500111188Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Oct 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in salivary gland cancer (SGC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Major Pathological Response rate. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on ChiCTR2500111188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111188.